Partnering Interest In Infectious Disease Space Showing Promise Beyond HCV Hotspot
Antiviral agents and vaccines for indications beyond the red-hot hepatitis C indication highlight the infectious diseases track at this year’s Therapeutic Area Partnerships conference.
You may also be interested in...
Biota and Nabi have proposed a merger that will give the Australian company access to the U.S. biotech market and increase its cash on hand.
Agenus will have sufficient cash to last through 2013 as it focuses on furthering its immunotherapeutics, including HerpV for genital herpes and Prophage Series G vaccines for glioma.
Pear Therapeutics’ Somryst insomnia treatment tool has become the first FDA-cleared product that was reviewed through the agency’s Software Precertification Pilot Program.